Scangos Leaves Biogen Transformed And Transitioning
Executive Summary
CEO George Scangos built Biogen into an innovative biotech, but his departure, coming as the company dusts itself off after a fall from glory, increased speculation Biogen could become a takeout target.
You may also be interested in...
Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.
R&D Head Ehlers Bows Out As Confidence In Biogen's Pipeline Suffers From Setbacks
EVP Michael Ehlers swaps public company scrutiny for early-stage, venture-funded opportunities at Apple Tree Partners and Limelight Bio, while CMO and longtime Biogen executive Alfred Sandrock reclaims R&D oversight role.
Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus
Biogen’s Chief Commercial Officer Michel Vounatsos will succeed CEO George Scangos effective Jan. 6. The appointment of the longtime Merck executive appears to suggest a renewed emphasis on the commercial landscape for a big biotech that has recently played up R&D.